EB-101

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epidermolysis Bullosa

Conditions

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa

Trial Timeline

Jan 10, 2020 → Oct 18, 2022

NCT ID

NCT04227106

About EB-101

EB-101 is a phase 3 stage product being developed by Abeona Therapeutics for Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT04227106. Target conditions include Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa.

What happened to similar drugs?

0 of 6 similar drugs in Epidermolysis Bullosa were approved

Approved (0) Terminated (1) Active (5)

🔄KB803 + PlaceboKrystal BiotechPhase 3

🔄Topical Beremagene GeperpavecKrystal BiotechPhase 3

🔄Open Label Topical Beremagene Geperpavec (B-VEC)Krystal BiotechPhase 3

🔄SD-101-6.0 cream + Placebo (SD-101-0.0) creamAmicus TherapeuticsPhase 3

❌SD-101-6.0 creamAmicus TherapeuticsPhase 3

🔄EB-101 Surgical application of RDEB woundsAbeona TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05708677	Pre-clinical	Recruiting	Feb 9, 2021	Aug 1, 2036	RDEB
NCT04227106	Phase 3	Completed	Jan 10, 2020	Oct 18, 2022	Epidermolysis Bullosa

Competing Products

13 competing products in Epidermolysis Bullosa

See all competitors

Product	Company	Stage	Hype Score
Efgartigimod	Argenx	Phase 1/2	36
KB803 + Placebo	Krystal Biotech	Phase 3	44
Topical beremagene geperpavec + Placebo gel	Krystal Biotech	Phase 1/2	29
Topical Beremagene Geperpavec	Krystal Biotech	Phase 3	37
Open Label Topical Beremagene Geperpavec (B-VEC)	Krystal Biotech	Phase 3	37
SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%)	Amicus Therapeutics	Phase 2	32
SD-101-6.0 cream + Placebo (SD-101-0.0) cream	Amicus Therapeutics	Phase 3	37
SD-101-6.0 cream	Amicus Therapeutics	Phase 3	29
SD-101 dermal cream (6%)	Amicus Therapeutics	Phase 2	24
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets	Abeona Therapeutics	Phase 1/2	22
EB-101 Surgical application of RDEB wounds	Abeona Therapeutics	Phase 3	34
VPD-737	Vyne Therapeutics	Phase 2	25
Serlopitant Tablet + Placebo Oral Tablet	Vyne Therapeutics	Phase 2	25